27472389|t|Dimerization of EGFR and HER2 induces breast cancer cell motility through STAT1 -dependent ACTA2 induction
27472389|a|The dimerization of EGFR and HER2 is associated with poor prognosis such as induction of tumor growth and cell invasion compared to when EGFR remains as a homodimer. However, the mechanism for events after dimerization in breast cancer models is not clear. We found that expressions of alpha-smooth muscle actin (ACTA2) and signal transducer and activator of transcription 1 (STAT1) significantly increased with transient or stable overexpression of HER2 in EGFR - positive breast cancer cells. ACTA2 and STAT1 expression was also increased in HER2 - positive breast cancer patients. In contrast, ACTA2 expression was decreased by HER2 siRNA. Next, we investigated the co-relation between STAT1 and ACTA2 expression. Basal ACTA2 expression was significantly decreased by treatment with the STAT1 inhibitor fludarabine or the JAK2 inhibitor AG490. In contrast, ACTA2 expression was increased by STAT1 overexpression. Levels of ACTA2, STAT1, and HER2 were increased and relapse free survival was decreased in high-risk breast cancer patients. We also investigated the effect of ACTA2 on cell motility, which was suppressed by ACTA2 shRNA overexpression in MDA-MB231 HER2 and 4T1 mammary carcinoma cells. The number of lung metastatic nodules was significantly decreased in ACTA2 knockdown mice. Taken together, these results demonstrated that induction of ACTA2 by EGFR and HER2 dimerization was regulated through a JAK2 / STAT1 signaling pathway, and aberrant ACTA2 expression accelerated the invasiveness and metastasis of breast cancer cells.
27472389	16	20	EGFR	T103	UMLS:C0034802
27472389	25	29	HER2	T103	UMLS:C0069515
27472389	38	51	breast cancer	T038	UMLS:C0006142
27472389	52	65	cell motility	T038	UMLS:C0007608
27472389	74	79	STAT1	T103	UMLS:C0287920
27472389	91	96	ACTA2	T103	UMLS:C2716282
27472389	127	131	EGFR	T103	UMLS:C0034802
27472389	136	140	HER2	T103	UMLS:C0069515
27472389	165	174	prognosis	T058	UMLS:C0033325
27472389	213	226	cell invasion	T038	UMLS:C2699153
27472389	244	248	EGFR	T103	UMLS:C0034802
27472389	329	342	breast cancer	T038	UMLS:C0006142
27472389	378	389	expressions	T038	UMLS:C1171362
27472389	393	418	alpha-smooth muscle actin	T103	UMLS:C2716282
27472389	420	425	ACTA2	T103	UMLS:C2716282
27472389	431	481	signal transducer and activator of transcription 1	T103	UMLS:C0287920
27472389	483	488	STAT1	T103	UMLS:C0287920
27472389	539	553	overexpression	T038	UMLS:C1514559
27472389	557	561	HER2	T103	UMLS:C0069515
27472389	565	569	EGFR	T103	UMLS:C0034802
27472389	572	580	positive	T033	UMLS:C1446409
27472389	581	594	breast cancer	T038	UMLS:C0006142
27472389	595	600	cells	T017	UMLS:C0007634
27472389	602	607	ACTA2	T103	UMLS:C2716282
27472389	612	617	STAT1	T103	UMLS:C0287920
27472389	618	628	expression	T038	UMLS:C1171362
27472389	651	655	HER2	T103	UMLS:C0069515
27472389	658	666	positive	T033	UMLS:C1446409
27472389	667	680	breast cancer	T038	UMLS:C0006142
27472389	704	709	ACTA2	T103	UMLS:C2716282
27472389	710	720	expression	T038	UMLS:C1171362
27472389	738	748	HER2 siRNA	T103	UMLS:C1099354
27472389	796	801	STAT1	T103	UMLS:C0287920
27472389	806	811	ACTA2	T103	UMLS:C2716282
27472389	812	822	expression	T038	UMLS:C1171362
27472389	830	835	ACTA2	T103	UMLS:C2716282
27472389	836	846	expression	T038	UMLS:C1171362
27472389	878	887	treatment	T058	UMLS:C0087111
27472389	897	912	STAT1 inhibitor	T103	UMLS:C1254351
27472389	913	924	fludarabine	T103	UMLS:C0059985
27472389	932	946	JAK2 inhibitor	T103	UMLS:C1254351
27472389	947	952	AG490	T103	UMLS:C0381241
27472389	967	972	ACTA2	T103	UMLS:C2716282
27472389	973	983	expression	T038	UMLS:C1171362
27472389	1001	1006	STAT1	T103	UMLS:C0287920
27472389	1007	1021	overexpression	T038	UMLS:C1514559
27472389	1033	1038	ACTA2	T103	UMLS:C2716282
27472389	1040	1045	STAT1	T103	UMLS:C0287920
27472389	1051	1055	HER2	T103	UMLS:C0069515
27472389	1114	1123	high-risk	T033	UMLS:C0332167
27472389	1124	1137	breast cancer	T038	UMLS:C0006142
27472389	1183	1188	ACTA2	T103	UMLS:C2716282
27472389	1192	1205	cell motility	T038	UMLS:C0007608
27472389	1231	1242	ACTA2 shRNA	T103	UMLS:C2930586
27472389	1243	1257	overexpression	T038	UMLS:C1514559
27472389	1261	1270	MDA-MB231	T017	UMLS:C1512505
27472389	1271	1275	HER2	T103	UMLS:C0069515
27472389	1280	1307	4T1 mammary carcinoma cells	T017	UMLS:C1512505
27472389	1323	1346	lung metastatic nodules	T033	UMLS:C0034079
27472389	1378	1383	ACTA2	T103	UMLS:C2716282
27472389	1384	1398	knockdown mice	T204	UMLS:C0206745
27472389	1461	1466	ACTA2	T103	UMLS:C2716282
27472389	1470	1474	EGFR	T103	UMLS:C0034802
27472389	1479	1483	HER2	T103	UMLS:C0069515
27472389	1521	1525	JAK2	T103	UMLS:C0169661
27472389	1528	1533	STAT1	T103	UMLS:C0287920
27472389	1534	1551	signaling pathway	T038	UMLS:C0037080
27472389	1566	1571	ACTA2	T103	UMLS:C2716282
27472389	1572	1582	expression	T038	UMLS:C1171362
27472389	1572	1582	expression	T038	UMLS:C1171362
27472389	1599	1611	invasiveness	T038	UMLS:C0027626
27472389	1616	1626	metastasis	T038	UMLS:C0027627
27472389	1630	1643	breast cancer	T038	UMLS:C0006142
27472389	1644	1649	cells	T017	UMLS:C0007634